Institutional investors purchased a net $69.4 thousand shares of RNN during the quarter ended December 2014 and now own 4.55% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 310.8 Thousand shares of Rexahn Pharmaceuticals In...
BLACKROCK FUND ADVISORS Bought 283.8 Thousand shares of Rexahn Pharmaceuticals In...